MedPath

Protein C

Generic Name
Protein C
Brand Names
Balfaxar, Beriplex, Ceprotin, Kcentra, Octaplex
Drug Type
Biotech
Unique Ingredient Identifier
Y2RU654EXB
Background

Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation.

The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.

Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.

Indication

Protein C concentrate is indicated for pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. It is also found as a component of some prothrombin complex concentrate (i.e. Factor IX Complex (Human)) formulations, such as Kcentra.

Associated Conditions
Purpura Fulminans, Venous Thrombosis (Disorder)

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Phase 1
Completed
Conditions
Congenital Protein C Deficiency
Interventions
First Posted Date
2021-08-02
Last Posted Date
2025-05-07
Lead Sponsor
Takeda
Target Recruit Count
5
Registration Number
NCT04984889
Locations
🇯🇵

Chiba Children's Hospital, Chiba, Japan

🇯🇵

Nara Medical University Hospital, Kashihara, Nara, Japan

🇯🇵

Chiba University Hospital, Chiba, Japan

and more 1 locations

Administration of Protein C Concentrates in Adult Critically Ill Septic Patients

Phase 3
Terminated
Conditions
Sepsis
Interventions
First Posted Date
2012-10-12
Last Posted Date
2015-12-15
Lead Sponsor
Università Vita-Salute San Raffaele
Registration Number
NCT01705808
Locations
🇮🇹

Ospedale San Raffaele di Milano, Italy, Milano, Italy

Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.

Phase 2
Completed
Conditions
Sepsis
Septic Shock
Interventions
First Posted Date
2011-08-08
Last Posted Date
2015-12-02
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
60
Registration Number
NCT01411670
Locations
🇮🇹

Departement of Anesthesiology and Intensive Care of the University of Rome La Sapienza, Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath